ArticleOncoimmunology2014
Novel immune checkpoint blocker approved for the treatment of advanced melanoma.
Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Immune checkpoint TIM-3 in tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- Cancer immunotherapy in progress-an overview of the past 130 years.International immunology · 2025Review
- Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Toll-like receptors in health and disease.MedComm · 2024Review
- The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.Frontiers in oncology · 2023Article
- Review
- Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome.Scientific reports · 2021Article
- Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.Journal for immunotherapy of cancer · 2019Article
- Bugs as Cancer Drugs: Challenges and Opportunities.Molecular and cellular biology · 2019Article
- Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses.Cancers · 2019Review
- Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.Oncoimmunology · 2016Article
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Oncoimmunology · 2016Review
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.Oncoimmunology · 2016Review
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Gastric cancer: The times they are a-changin'.World journal of gastrointestinal oncology · 2015Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Oncoimmunology · 2015Article
- Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology · 2015Article
- Trial Watch: Peptide-based anticancer vaccines.Oncoimmunology · 2015Review
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.Oncoimmunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.